Background Short-acting β2-agonists (SABA) overuse is associated with asthma morbidity and mortality. The SABA use IN Asthma (SABINA) program aimed to describe the global use of SABA in patients with asthma. SABINA III study was a cross-sectional study covering 24 countries. Methods We performed statistical analysis of the Russian population (618 patients recruited in 12 centers) from the SABINA III study. In this study in patients aged ≥12 years, data on disease characteristics and asthma treatments were collected using real-time electronic case report forms. Patients were classified by asthma severity and control according to the 2017 GINA. All variables (asthma severity and control, number of severe exacerbations, SABA and other medications use) were analyzed descriptively only, no hypothesis was tested. Results Majority of the study population consisted of patients with moderate/severe asthma (78.5%), while mild asthma was seen in 21.5%. Asthma was uncontrolled in 36.1% of patients and partly controlled in 33.5%. More than 80% of patients were treated with ICS/LABA fixed-dose combination. Almost half of all patients (47.0%) had at least 1 severe exacerbation in the previous 12 months. SABA over-prescription (≥3 canisters per year) was seen in 37% of patients. The frequency of SABA over-prescription was similar in patients with mild (35%) and moderate/severe (38%) asthma. SABA was purchased over-the-counter (OTC) in the past 12 months by 30.1% of all patients, and 14% purchased ≥3 canisters of SABA per year. About 91% of patients who purchased SABA OTC already received prescriptions for SABA, of whom 59% were prescribed ≥3 canisters per year. Conclusion Russia is seeing very high level of SABA over-prescription. This is potentially associated with poor asthma control and frequent severe exacerbations. Over-prescription may serve as the main cause for SABA overuse in Russia. To reduce SABA overuse and improve overall asthma control in Russia, it is necessary to educate not just the patients but also the doctors, while actively implementing up-to-date asthma treatments.

In assessing occupational morbidity in the Orenburg region for 2006-2015. revealed a growth trend from 0.8 to 1.5%. The reasons for the development of pathology are chemical (33.8%) and physical (52.4%) factors, the severity of labor (7.1%). Among the causes of morbidity from the type of activity, there are mining operations (35.4%), processing (25.4%) and metallurgical (24.7%) production.

Short-acting β2 -agonists (SABA) overuse is associated with negative outcomes in asthma patients. There is a lack of actual data about patterns of SABA overuse in the Russian population with asthma.The aim. To investigate patterns of SABA overuse in the Russian population with asthma.Methods. Data from the Russian population of “SABA use IN Asthma (SABINA) III” study were analyzed. SABINA III was a cross-sectional observational study covering 24 countries. Adults and adolescents with a documented diagnosis of asthma for at least 12 months were enrolled in the study. Data on disease characteristics and asthma treatments during previous 12 months were collected using real-time electronic case report forms and were analyzed with methods of descriptive statistics.Results. Majority of the Russian population (n = 618) consisted of patients with moderate/ severe asthma (78.5%). Asthma was uncontrolled or partly controlled in 70% of patients. SABA over-prescription (≥ 3 canisters per year) was seen in 37% of patients. The frequency of SABA over-prescription was similar in patients with mild (35%) and moderate/severe (38%) asthma. SABA was purchased over-the-counter (OTC) in the past 12 months by 30% of all patients, while 14% purchased ≥ 3 canisters of SABA per year. More than 90% of patients who purchased SABA OTC, already received prescriptions for SABA, of whom 59% were prescribed ≥ 3 canisters per year.Conclusion. Russia is faced with very high level of SABA overuse. Over-prescription is the main cause for SABA overuse. To reduce SABA overuse, it is necessary to educate both patients and doctors, and actively implement up-to-date asthma treatments.

The article presents the results of a study of attitudes towards illness, quality of life and their relationship in hospitalized patients. An empirical study of three groups of hospitalized patients aged 40 to 80 years was carried out: with ischemic heart disease (group I, n = 22; 55,3(13,8) years), with chronic obstructive pulmonary disease (group II, n=22; 53,7(12,0) years) and with osteochondrosis (group III, n=22; 59,6(14,8) years). Distribution by sex in all groups – 50% of men and 50% of women. To determine the type of attitude towards the disease, the Bekhterev Institute's questionnaire "Type of attitude towards the disease" (TOBOL) was used, the quality of life – the questionnaire of the Assessment of the quality of life (SF-36). The results of the study showed that in patients of all groups maladaptive types of attitudes towards the disease prevailed: Group I – hypochondriacal; apathetic; Group II – neurasthenic, dysphoric, paranoid; Group III – anxious, apathetic types. The quality of life of patients of all groups did not differ from each other: the physical component of health was assessed as low; the psychological component of health was average. A high rate of pain syndrome and social functioning was found in patients in group I, and in general health in patients in group II. Factor analysis revealed the relationship between the general state of health of patients (the patient's subjective assessment of his health) and the type of attitude towards the disease. Most of the patients needed psychological help to correct the type of attitude towards the disease and improve the quality of life. The revealed relationship between the internal picture of the disease and the quality of life requires additional research.